Imaging of malignancies of the biliary tract- an update by unknown
Hennedige et al. Cancer Imaging 2014, 14:14
http://www.cancerimagingjournal.com/content/14/1/14REVIEW Open AccessImaging of malignancies of the biliary tract- an
update
Tiffany Priyanthi Hennedige1, Wee Thong Neo1 and Sudhakar Kundapur Venkatesh2*Abstract
Malignancies of the biliary tract include cholangiocarcinoma, gallbladder cancers and carcinoma of the ampulla of
Vater. Biliary tract adenocarcinomas are the second most common primary hepatobiliary cancer. Due to their slow
growing nature, non-specific and late symptomatology, these malignancies are often diagnosed in advanced stages
with poor prognosis. Apart from incidental discovery of gall bladder carcinoma upon cholecystectomy, early stage
biliary tract cancers are now detected with computed tomography (CT) and magnetic resonance imaging (MRI)
with magnetic resonance cholangiopancreatography (MRCP). Accurate characterization and staging of these indolent
cancers will determine outcome as majority of the patients’ are inoperable at the time of presentation. Ultrasound is
useful for initial evaluation of the biliary tract and gallbladder masses and in determining the next suitable modality for
further evaluation. Multimodality imaging plays an integral role in the management of the biliary tract malignancies.
The imaging techniques most useful are MRI with MRCP, endoscopic retrograde cholangiopancreatography
(ERCP), endoscopic ultrasound (EUS) and positron emission tomography (PET). In this review we will discuss
epidemiology and the role of imaging in detection, characterization and management of the biliary tract
malignancies under the three broad categories of cholangiocarcinomas (intra- and extrahepatic), gallbladder
cancers and ampullary carcinomas.
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Biliary tract cancer is the second most common primary
hepatobiliary malignancy after hepatocellular carcinoma.
Malignancies may occur along any part of the biliary tract
from the ampulla of Vater to the smallest intrahepatic
ductules and the gallbladder [1]. The entire biliary tree,
including the gallbladder is lined with a simple columnar
epithelium and malignant transformation of this epithelium
gives rise to predominantly adenocarcinomas [2]. The
pathogenesis of biliary tract and gallbladder carcinoma
is thought to be secondary to an evolutionary sequence
from metaplasia to dysplasia to carcinoma. Metaplasia
usually occurs in the setting of inflammation and
chronic injury. Dysplasia of the biliary tract, is considered
as pre-invasive biliary neoplasia and can occur in up to
40% to 60% of patients with invasive carcinoma, one third* Correspondence: venkatesh.sudhakar@mayo.edu
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article, unless otherwise stated.of patients with sclerosing cholangitis, and found inciden-
tally in 1 to 3.5% of cholecystectomy specimens [3,4].
Classically, the cancers of the biliary tract were sepa-
rated into three categories: (i) cancer of the intrahepatic
biliary tract, (ii) cancer of the gallbladder and extrahepatic
bile ducts, and (iii) cancer of the ampulla of Vater [5]. The
term cholangiocarcinoma was initially used to refer only
to the primary tumors of the intrahepatic bile ducts and is
now extended to include intrahepatic, perihilar, and distal
extrahepatic tumors of the bile ducts [6] (Figure 1).
Gallbladder cancer is defined as cancer arising from the
gallbladder and the cystic duct. Ampullary cancers are
rare and have better prognosis than cancers of the distal
bile duct. Cancers arising from the distal common bile
duct immediately adjacent to the ampulla of Vater tend
to behave clinically similar to the cancers of the ampulla
of Vater, head of pancreas and the duodenal bulb and
therefore often considered under the broad category of
periampullary carcinomas [7].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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Figure 1 Malignancies of the biliary tract. Diagram showing the biliary tract and the various malignancies arising from the tract. The
cholangiocarcinomas are illustrated according to current classification into anatomical and morphological subtypes.
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symptoms from abdominal pain or jaundice. Biliary
tract malignancies are slow growing and often diag-
nosed late with poor prognosis due to the non-specific
and late stage symptomatology. The symptoms may
occur early if the tumor is located in the common hepatic
duct, the common bile duct or the ampulla of Vater. Apart
from incidental discovery upon cholecystectomy, early
stage biliary tumors are now increasingly diagnosed
with computed tomography (CT) and magnetic resonance
imaging (MRI).
Clinical history, geographic background, risk factors,
patient’s age and gender are often crucial for arriving at
diagnosis of these tumors. Accurate characterization and
staging of the malignancies will determine resectability
and impact on subsequent management. Multimodality
imaging plays a deep and integral role in the management
of malignancies of the biliary tract. The techniques most
useful are MRI with magnetic resonance cholangiopancrea-
tography (MRCP), positron emission tomography (PET),
endoscopic retrograde cholangiopancreatography (ERCP)
and endoscopic ultrasound (EUS). In this review, we will
discuss the role of imaging in detection, characterization
and management of the biliary tract malignancies under the





CCA is the most common biliary malignancy [8] but is a
rare tumor that comprises less than 2% of all cancers
[9]. It arises from bile duct epithelium and is the second
most common primary hepatobiliary cancer after hepa-
tocellular carcinoma (HCC). Among gastrointestinal tu-
mors, it is the most difficult to detect and diagnose and
has a poor prognosis with a 5-year survival rate of less
than 5% [10]. CCA is uncommon in many parts of the
world such as Europe and the USA with incidence esti-
mates ranging from 0.8 to 2 per 100,000 [11]. However,
there is a distinct geographic variation in their incidence,
with the highest prevalence in Southeast Asia [12].
This reflects regional differences in risk factors and
epidemiology. Risk increases with age, with peak preva-
lence occurring in the 7th decade and has a slight male
predilection [13].
At histopathology, 95% of cases are adenocarcinomas
[14]. The histological grade of tumors can range from
well differentiated to undifferentiated types. Other tumor
Hennedige et al. Cancer Imaging 2014, 14:14 Page 3 of 21
http://www.cancerimagingjournal.com/content/14/1/14types include squamous cell carcinoma, adenosquamous
carcinoma and small cell carcinoma.
Generally CCAs occur sporadically with no identifiable
risk factors. Chronic biliary inflammation is a common
risk factor of CCA [15]. Well-documented risk factors
include primary sclerosing cholangitis (PSC), choledo-
chal cyst, familial polyposis, hepatolithiasis, congenital
hepatic fibrosis, clonorchiasis and a history of exposure
to thorotrast [13]. PSC is the best-known risk factor with
a lifetime prevalence of CCA ranging from 5-15% and
an overall risk of 0.5%-1.5% per year [16]. Nearly 50% of
patients are diagnosed with CCA within a year of diag-
nosis of PSC [16]. Patients with cystic bile duct disorders
like Caroli’s disease and choledochal cyst have high life-
time incidence of CCA ranging from 6% to 30% [17].
They also tend to have CCA diagnosed at a younger age
than the general population [12,17] and many still de-
velop CCA after resection of choledochal cysts. A higher
prevalence of positive anti–hepatitis C virus antibody has
also been reported to be associated with CCA and the risk
of developing CCA in cirrhotic patients is ten-fold
higher than the general population [12,18]. In Southeast
Asia where the tumor is relatively more common, the
associated risk factors are liver flukes (Opisthorchis
viverini and Clonorchis sinensis) and chronic typhoid car-
riers with the latter carrying a six-fold increased risk of all
hepatobiliary malignancies [14]. In addition, a genetic pre-
disposition is suggested with a mutation in the p53 tumor
suppressor and k-ras genes seen in intrahepatic and extra-
hepatic CCA respectively [19]. Lifestyle factors including
heavy alcohol use, diabetes and obesity are also more
prevalent in patients with CCA [20]. A strong association
exists between Thorotrast, a radiologic contrast agent
used before 1960, and the development of cholangiocarci-
noma several years after exposure [12].
CCA classification and morphology
CCA are classified based on their anatomic location as
intrahepatic CCA (iCCA), perihilar CCA (pCCA) and distal
(dCCA) subtypes [6]. These different types are regarded as
distinct entities from a treatment point of view [8]. The
intrahepatic type, iCCA accounts for 10%, pCCA for 25-
50% and dCCA for 40-65% of all CCA [21]. Some authors
have also divided extrahepatic CCA into upper third (hilar),
middle third and lower third [22]. CCA can also be classi-
fied on the basis of their macroscopic growth pattern into
three types: (1) mass-forming exophytic type, which typic-
ally appears as a hepatic parenchymal mass; (2) periductal
infiltrative type, of which tumor growth progresses along
the bile duct longitudinally. This often results in upstream
biliary tree dilatation and (3) intraductal polypoid type
that proliferates focally within the lumen of the diseased
bile duct [22]. Intrahepatic CCA are often of the mass-
forming exophytic type, whereas extrahepatic variantsmostly infiltrate longitudinally along the bile ducts [9].
The intraductal polypoid type is rare and can manifest in
any of the subtypes. CCA can also exhibit a combination
of growth patterns, and this is more frequently seen with
intrahepatic tumors.
These gross growth-type morphologic characteristics
enable interpretation of imaging features and assist in
the differential diagnosis. More importantly, they can
predict tumor dissemination and prognosis, which aids
subsequent management including planning of surgical
approach. More than 90% of CCA are well to moderately
differentiated adenocarcinomas with desmoplastic reaction
and early perineural invasion [23]. Malignancies associated
with cystic anomalies of the bile duct or bile duct stones
may be adenosquamous or squamous carcinomas.
Diagnosis of CCA
The diagnosis of CCA can be difficult due to silent
growth and non-specific symptoms. Diagnosis requires
a high degree of clinical suspicion in the appropriate
setting of clinical presentation, laboratory, endoscopic
and imaging findings. Patients with known risk factors
need aggressive diagnostic work-up to confirm the diag-
nosis of CCA. Tumor markers like carbohydrate antigen
19–9 (CA19-9) can be raised, particularly with iCCA
type [8]. Cut-off value of 129U/mL or greater detects
iCCA in patients with PSC with a sensitivity and specifi-
city of 79% and 98% respectively [24]. The primary role
of imaging in CCA is to characterize the primary tumor,
establish the presence or absence of satellite nodules or
distant metastases, and identify the tumor’s relationship to
the hepatic veins, inferior vena cava, the hepatic inflow
pedicles, and the biliary tree. CT may be useful for volu-
metric assessment of potential liver remnants if patients
are considered for surgical resection. Imaging techniques
should also aim to identify extrahepatic lymph node dis-
ease as well as distant metastatic disease such as pulmon-
ary or peritoneal metastases. Typically, patients with CCA
are assessed with a CT of the chest, abdomen, and pelvis.
An MRI may alternatively be used to stage the tumor.
Intrahepatic CCA (iCCA)
The iCCA also known as peripheral cholangiocarcinoma
(Figures 2, 3, 4, 5, 6, and 7) occur distal to second order
bile ducts within the hepatic parenchyma and is the
second most common intrahepatic primary tumor. iCCA
arise from biliary epithelium at any portion of the intra-
hepatic biliary system, from the mucin-producing cylin-
drical cells lining the segmental bile ducts or cuboidal
cholangiocytes without mucin production that line the
bile ductules [25]. The histopathology can resemble
adenocarcinoma of almost any organ. iCCA are highly
infiltrative and contain areas of fibrosis, necrosis and
mucin. Active tumor growth is frequently found at the
Figure 2 Examples of intrahepatic cholangiocarcinoma (iCCA) on ultrasound in two different patients. Mass forming iCCA may present as
a well-defined hypoechoic mass (arrow, a) or as an ill-defined heterogeneous isoechoic mass (arrowheads, b).
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the mass-forming (Figures 2, 3, 6 and 7), accounting
for 80% of the iCCA and this subtype spreads via venous
and lymphatic vessels [26]. The periductal-infiltrating type
spreads mainly longitudinally along and within the bile
duct often resulting in dilatation of the peripheral ducts
(Figure 5). This also tends to spread along the lymphatics.
The intraductal-growth type (Figure 4) proliferates towards
the lumen and often has papillary growth characteristics.
Papillary intrahepatic CCA occasionally produces abundant
mucin that can result in massive expansion of the duct and
present as a cystic mass mimicking cystadenocarcinoma
[27]. The infiltrating type with mass forming features has
the worst prognosis among the intrahepatic types [22]. TheFigure 3 CT and MRI appearances of mass forming type of iCCA. Top
(b), portal venous phase (c) and delayed phase (d) CT images. Bottom row
venous phase (f), delayed phase (g), and 20-minute delay post Gd-EOB-DT
contrast enhancement characteristics on both CT and MRI with peripheral
the portal venous and delayed phases without any washout. In the hepato
suggesting a non-hepatocellular tumor.rarest form of intrahepatic CCA is the superficial spreading
type and has a better outcome [28]. iCCA presents with
non-specific symptoms such as abdominal pain, weight loss
and night sweats and uncommonly jaundice.
Imaging
The imaging features of iCCA are dependent on their size
and proportion of fibrosis, necrosis and mucin content.
Ultrasound
Intrahepatic cholangiocarcinoma has variable echogeni-
city on sonography but tends to be hyperechoic [29] and
simulate other masses (Figure 2). The internal architec-
ture of the tumor is usually homogeneous, but it can berow: non contrast enhanced (a), post contrast enhanced arterial phase
: post contrast enhanced MRI images in arterial phase (e), portal
PA image (h). The mass is iso- to hypodense to liver and shows similar
rim like arterial phase enhancement with centripetal enhancement in
biliary phase there is no uptake of Gd-EOB-DTPA by the mass
Figure 4 Polypoid type iCCA. Axial T2 sections (a, b) and MRCP (c) demonstrating an isointense filling defect (white arrow) in the right hepatic
duct and extending into the common hepatic duct with dilation of intrahepatic ducts. Post contrast enhanced T1-weighted images (d-f) shows
the mildly enhancing filling defect representing intraductal papillary neoplasm which extended from just under hepatic capsule filling right
hepatic ducts to 3 cm below the confluence of right and left hepatic ducts.
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sue, mucin and calcification. With contrast enhanced
ultrasound, iCCA may show washout and mimic HCC
[30] and therefore is not recommended as the sole im-
aging technique for conclusive diagnosis of HCC [31].Figure 5 Mixed type iCCA. T2-weighted axial (a), MRCP (b), T1-weighted
a predominantly periductal thickening (stricturing iCCA) and also mass form
intrahepatic ducts on MRCP (arrowheads).CT
On CT, intrahepatic cholangiocarcinomas can be well
defined or infiltrative, and they lack the fibrous capsules
found in HCC [29-32]. iCCA are typically hypo- or iso-
attenuating relative to normal hepatic parenchyma onaxial (c) and post contrast T1-weighted axial (d) images demonstrating
ing (arrow) in the right lobe liver. Note the separation of the right
Figure 6 Cirrhosis of liver with iCCA. T2-weighted axial (a), T1-weighted axial (b) and post gadolinium enhanced T1-weighted axial arterial
phase (c), portal venous phase (d) and delayed phase (e) images showing iCCA as an iso- to hyperintense lesion (arrow) in posterior right lobe
with typical arterial phase rim like enhancement and progressive central enhancement through delayed phase without any washout. The liver
parenchyma is heterogeneous and nodular consistent with cirrhosis.
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during the arterial and portal venous phases with en-
hancement only in the delayed phase (Figures 3, 4, 5 and
6). These findings reflect their hypovascular desmoplastic
composition [13,33]. The periphery of the malignant mass,
in which active tumor growth is found, enhances rapidly
after contrast enhancement and becomes isodense or
hypodense during the portal phase [34]. Fibrous tissue, in
the central area of the tumor, does not enhance during the
early phase but becomes hyperdense during the delayed
phase to 20 minutes later [34,35]. The central portion of
the tumor remains hypodense, however, with necrotic
or mucin-producing tumors. The degree of enhancement
varies among tumors and some small mass-forming intra-
hepatic CCA are arterially enhancing, mimicking HCC.
The use of delayed phase increases diagnostic confidence
in nearly half of the cases [32].
Tumor enhancement on delayed CT imaging has actually
been correlated with outcome. Asayama and colleagues
[36] found that tumors that exhibited delayed enhancement
on CT in more than two thirds of their volume had an in-
creased amount of fibrous stroma and perineural invasion
and were associated with a worse prognosis. The dense
fibrotic nature of the tumor may result in capsular re-
traction in about one-fifth of cases [37-39].Figure 7 PET-CT of iCCA. Axial PET-CT images showing a large FDG-avid
with FDG-avid portal lymph node (a, arrow head) and aortocaval lymph noMRI
The MR imaging features of iCCA differ according to its
pattern of growth. Mass-forming ICC is irregularly mar-
ginated and demonstrates signal intensity depending on
the degree of fibrosis, necrosis, hemorrhage and mucin
within the tumor [13] (Figures 3, 5 and 6). iCCA is typically
hypo to isointense on T1-weighted (T1W) and variably hy-
perintense on T2-weighted (T2W) imaging. The amount of
T2W hyperintensity is also determined by the pathological
subtype: the scirrhous subtype demonstrates relatively
lower signal intensity as compared to a well-differentiated
adenocarcinoma, owing to the fact that it is more fibrous
with less mucin and necrosis [9]. Occasionally, CCA can
be isointense to hepatic parenchyma on both T1W and
T2W imaging [40].
Following the intravenous administration of gadolinium
chelates, CCA typically show minimal or heterogeneous
enhancement at the tumor periphery on early images,
with progressive central enhancement on subsequent
delayed images [41] (Figures 3, 5 and 6) owing to the
fibrous composition [15]. The area of tumor with early
enhancement indicates active growth. Progressive and pro-
longed delayed enhancement is seen in areas of fibrosis
where there is decreased arterial blood supply with loose
connective tissue and abundance of intercellular matrix [9].iCCA (arrow) with central photopenia (*) indicating necrosis/fibrosis
de (b, arrow head) consistent with lymph node metastases.
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retraction may also be observed [42]. In addition, the en-
hancement pattern is slow and peripheral in the arterial
phase, with progressive concentric enhancement over
time like a ring [43]. Encasement of hepatic vessels with-
out thrombosis and hepatolithiasis are not uncommon
findings.
When hepatobiliary-specific contrast agents are used,
surrounding hepatic parenchyma enhances more because
of the hepatocyte uptake. As a result, iCCA will appear
relatively more hypointense (Figure 3) and early experi-
ence had indicated that this feature allows for better lesion
demarcation [44]. Both MRI and CT are comparable for
detection of satellite lesions.
Differentiating iCCA from HCC can be difficult espe-
cially if there is absence of progressive enhancement
pattern [45]. This is an important clinical issue since
iCCA can also occur in cirrhotic livers. Laboratory tests
are also useful in establishing the diagnosis, because
alpha-feto protein (AFP) levels are usually normal or only
slightly elevated in intrahepatic cholangiocarcinoma com-
pared with HCC. CA 19–9 may be increased. Up to 81%
of iCCA are characterized by a progressive contrast up-
take throughout the arterial and venous phase and later in
the delayed phase without a prompt washout on both CT
and MRI [45]. Hemangiomas also show progressive con-
trast enhancement but it has characteristic peripheral
nodular enhancement quite different from iCCA. In
one of the largest study, none of the iCCA showed the
characteristic imaging features of HCC [45]. A subtype
known as cholangiocellular carcinoma with mixed
histological features, including HCC and CCA may show
HCC imaging characteristics leading to diagnostic prob-
lems. A percutaneous biopsy is therefore required for final
diagnosis in cases of lesions that show atypical features
to confirm diagnosis especially if they are candidates for
surgical resection. Histological differentiation from me-
tastases can be improved by immunoprofiling with a
combination of cytokeratin (K) 7 and K20 immunohis-
tochemical staining [46].
PET
PET provides metabolic information on tumors, and
with regards to CCA, the high glucose uptake of bile
duct epithelium enables detection of tumors as small as
1 cm but is less helpful for infiltrative periductal tumours
[47,48]. The specificity of PET for the detection of mass-
forming intrahepatic CCA >1 cm in diameter has been
reported as 85-95% with a sensitivity of 100% [49]. A
drawback is its inability to differentiate malignant from
benign lesions limiting its use as a standalone imaging
modality in diagnosing CCA [47]. However, it has been
documented that PET can complement cross-section
imaging in identifying occult distant metastases (Figure 7)and detection of recurrence with previously treated/
resected CCA. Early data had also indicated that infor-
mation from PET scans could lead to a change in sur-
gical management due to detection of unsuspected
metastases [48].
Staging and treatment
The prognostic factors include tumor number and differ-
entiation, lymph node metastases and vascular invasion.
Regional lymph node metastases are an independent
predictor of survival. Three staging systems are available
for cholangiocarcinoma: The American Joint Cancer Com-
mittee/Union for International Cancer Control (AJCC/
UICC) TNM staging system [50], the liver cancer study
group of Japan (LSCGJ) staging system [22] and the
National Cancer center of Japan (NCCJ) staging system
[51]. However, these staging systems, although not sig-
nificantly different cannot provide prognostic informa-
tion and are also not able to stratify the patients to
treatment arms [8].
Surgical resection of iCCA is associated with high
rates of tumor recurrence and short survival periods.
Positive margins, lymph node metastases and cirrhosis
are associated with reduced survival time [21]. Liver
transplant is not considered a good option as the 5-year
rate of tumor recurrence is about 70% with a median
time of disease free survival of only 8 months [52].
Palliative treatment options include radiofrequency ab-
lation (RFA), trans arterial chemoembolization (TACE)
and trans arterial radio embolization (TARE) [53,54].
Systemic chemotherapy with combination of gemcita-
bine and cisplatin is probably the treatment standard in
patients with inoperable iCCA as it has been shown to
prolong survival times [55].
Perihilar CCA (pCCA)
The pCCA develops anywhere from the second order
biliary ducts to the common bile duct above and at the
site of cystic duct origin (Figures 8, 9, 10, 11, 12 and 13).
Klatskin’s tumors (Figure 12) are those pCCA that occur
at the confluence of right and left hepatic ducts and the
proximal common hepatic duct. Macroscopically they
can be nodular, sclerosing (periductal infiltrating) and
papillary subtypes [56]. Sclerosing or periductal infiltrating
CCA is the most common type and papillary adenocarcin-
omas are rare but have the best prognosis among the
CCA [57]. Most nodular and sclerosing tumors are well
to poorly differentiated tubular adenocarcinomas that
contain mucin glands lined by cuboidal epithelium and
abundant fibrous stroma.
Sclerosing CCA do not usually form a mass but grow
along the bile duct to produce a concentric thickening
of the bile duct that manifests as a poorly defined stricture
that eventually produces complete obliteration of the duct
Figure 8 Infiltrating pCCA. Axial post contrast enhanced T1-weighted MR image (a) and MRCP (b) images demonstrating an enhancing
stricture involving the left hepatic duct (arrow) with upstream dilatation of the left hepatic ducts.
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within the lumen and then penetrates the bile duct wall.
The nodular growth pattern with desmoplastic reaction
results in a hard mass with well-defined margins that
grows and almost always causes biliary obstruction [1].
Papillary tumors contain numerous papillary infoldings
supported by fibrovascular stalks and grow intraluminally.
They do not tend to invade bile duct wall and therefore
have a better prognosis [58]. pCCA typically spreads
by perineural invasion and lymphatic metastasis [8].
Lymphatic metastasis occurs most commonly to porta-
caval, superior pancreaticoduodenal, and posterior pan-
creaticoduodenal lymph nodes. The liver parenchyma,
the gastrohepatic and hepatoduodenal ligaments are com-
monly invaded by pCCA.
Most common clinical presentation is jaundice and it
occurs in 90% of patients and about 10% may present
with cholangitis. Systemic symptoms including malaise,
abdominal discomfort, nausea, anorexia and weight loss
may be seen in about half of patients [59,60]. Depending
on the location, they may cause chronic biliary obstruction
leading to atrophy of segments and lobes. Lobar hepatic
atrophy in association with biliary dilatation strongly
suggests pCCA. Unilateral hepatic lobe hypertrophy
with contralateral hepatic lobar atrophy known as
hypertrophy-atrophy complex occurs when there isFigure 9 Peripheral cholangiocarcinoma with involvement of conflue
parenchyma on axial contrast enhanced CT (a) with dilation of the left hepati
MRI image (b) with extension to the confluence causing mild dilatation of thunilobar biliary obstruction often with vascular encase-
ment [61].
Diagnosis
The diagnosis of pCCA is challenging and a multimodality
approach has to be taken in most of the cases. Imaging is
critical in diagnosis and management of pCCA. The role
of modern imaging, after excluding metastatic disease, is
to determine the T stage that will guide surgical manage-
ment. Accurate reporting with assessment of the presence
of lobar atrophy, sectoral or main portal vein involvement
and tumor extension into secondary biliary radicals will
help guide the hepatobiliary surgeon to determine pre-
operatively the extent of local tumor involvement and the
surgical resection to be performed. In addition, determin-
ation of the presence of distant disease, lymphadenopathy,
or satellite hepatic metastases is paramount.
Tumor markers can be useful in combination with
other imaging tests and in cases of indeterminate biliary
strictures. In patients with PSC, CA19-9 has sensitivity
and specificity of 79%and 98% respectively at serum con-
centration >129U/ml [62]. In patients without PSC, a
CA19-9 > 100U/ml has sensitivity of 76% and a negative
predictive value of 92% compared to those with benign
strictures [24]. It should be noted however that nearly
10% of the population may not secrete CA19-9 andnce. Infiltrating pCCA of the left hepatic duct (arrow) isodense to liver
c ducts. The ductal thickening is hyperintense (arrow) on T2-weighted
e right hepatic ducts demonstrated better on MRCP (c).
Figure 10 CCA of common hepatic duct with involvement of confluence. Contrast enhanced CT (a), T2-weighted MRI (b) and MRCP (c)
images demonstrating thickened and enhancing common hepatic duct (arrow) with involvement of the confluence and upstream dilatation
of the intrahepatic ducts. The ductal thickening appears hypointense (arrow) to the surrounding dilated bile ducts on T2-weighted MRI image
(b). The involvement of the confluence is demonstrated better on MRCP.
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[63]. Differential diagnosis of pCCA includes lymph nodes,
benign strictures and rarely lymphoma or sarcoma involv-
ing the bile ducts [37-39].
Ultrasound
Ultrasound is often the initial imaging study in patients
presenting with obstructive jaundice. This modality is
useful in ruling out benign causes of bile duct obstruc-
tion, including choledocholithiasis, and is reliable in
demonstrating the intrahepatic ductal anatomy and the
proximal level of obstruction (Figure 11). The sensitivityFigure 11 CCA of common hepatic duct with involvement of confluen
mass (arrow) filling the common hepatic duct with upstream dilatation of
was sampled positive for carcinoma. Contrast enhanced CT in arterial phas
within the duct and no major vascular involvement. The ductal mass is hyp
image (f) and shows concentric post contrast enhancement (g). MRCP (h)
hepatic duct.and accuracy of ultrasound for diagnosis of extrahepatic
CCA is 89% and 80-95% respectively [33,64]. Often the
strictures and the mass are not visible on ultrasound;
however lesions that form masses and invade surrounding
liver parenchyma or involve portal vessels can be demon-
strated on ultrasound. Ultrasound findings are useful in
determining the next best imaging modality for complete
assessment of the tumor.
CT
CT has become the non-invasive diagnostic test of
choice for evaluation and staging of pCCA allowing force. Ultrasound with color flow overlay (a) showing an echogenic
the intrahepatic ducts. EUS image (b) showing a hilar lymph node and
e (c) and portal venous phase (d) showing enhancing mass (arrow)
erintense on T2-weighted image (e) and hypointense on T1-weighted
shows the confluence invasion and non- visualization of the common
Figure 12 MRCP of a classical Klatskin’s tumor. The confluence,
proximal hepatic ducts and proximal common hepatic duct are
strictured (arrow). The common bile duct is of normal caliber.
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obstruction (Figure 11) and review of the abdomen and
pelvis for distant spread [13].
Multidetector CT has 78.6%-92.3% accuracy for diag-
nosis of extrahepatic CCA [34] but has strong tendency
to underestimate the longitudinal extension of the tumor
[65]. The accuracy for detection of portal vein and arter-
ial involvement has been reported to be as high as 87%
and 93% respectively [66]. The accuracy of CT in the
assessment of resectability has been reported as 60-88%
with negative predictive values of 85-100% [67]. However,
its sensitivity in the detection of regional lymphadenop-
athy is only 54% and CT tends to underestimate the
extent of proximal tumour [68]. Also, streak artifacts’ and
secondary inflammatory changes that can occur when a
stent is placed limits evaluation with CT [69].
CT hepatic arteriography, CT portography and CT
venographic images provide a detailed pre-operative vas-
cular roadmap comparable to that provided by catheterFigure 13 Hilar CCA presenting as an intraluminal mass with biliary o
enhanced CT (a) and hypointense on axial T2-weighted image (b) with up
defect (arrow) representing the mass extending into the common bile ducangiography facilitating accurate surgical planning [13].
CT cholangiography provide details of the biliary anatomy
and are considered in cases where MR imaging is contra-
indicated or unavailable. CT cholangiography is superior
to conventional CT or US and equal to ERCP for diag-
nosis of pCCA [66]. A potential limitation of CT chol-
angiography is the dependence on the secretory function
of the biliary system that may be compromised in patients
with high-grade obstruction or significantly elevated
bilirubin levels [13].
MRI and MRCP
Diagnosis of the periductal infiltrating CCA can be dif-
ficult owing to the infiltrative nature of the tumor and
absence of a mass-like lesion. Typically, the main im-
aging features are biliary duct obstruction as evident
by proximal ductal dilatation, periductal thickening
and enhancement (Figure 12) [15,41]. As mentioned
previously, the intra-ductal mass type is rare, it typically
manifests as an enhancing intraductal mass associated
with proximal ductal dilation [15].
MRCP is an accurate method for anatomically mapping
the biliary tree. It does not require biliary instrumentation.
MRCP is now considered the radiological modality of
choice for evaluating patients with suspected CCA [43].
MRCP should be ideally performed before decompressing
the biliary tree. With MRCP, there is better assessment of
the extent of peripheral ductal involvement as compared
to ERCP (Figures 13 and 14). This is because ducts
proximal to an obstructing tumor may not adequately
fill during ERCP [43] (Figure 13). The reported accuracy
in determining the extent of bile duct tumors ranges
from 71% to 96% [43]. In addition, acquisition of 3D
data sets provides information useful for preoperative
management and surgical planning. MRI with MRCP
is the imaging technique of choice in many centers
secondary to its excellent soft tissue contrast that is
particularly useful for evaluation of infiltrating ductal
tumors [69]. MRI with MRCP has an accuracy of 66%
for detection of lymph node metastases [70], 78%
sensitivity and 91% specificity for portal vein invasionbstruction. The mass is isodense (arrow) on the coronal non-contrast
stream dilatation of the intrahepatic ducts. ERCP (c) shows a filling
t with no filling of the intrahepatic ducts.
Figure 14 Perihilar CCA arising from the cystic duct and proximal gall bladder (arrows) with invasion of common hepatic duct. The
pCCA is mildly hyperintense on T2-weighted image (a), hypointense on T1-weighted image (b) and shows post contrast enhancement (c). Both
MRCP (d) and ERCP (e) demonstrate the stricture of the common hepatic duct till the confluence above and cystic duct insertion below. The gall
bladder is not visualized on ERCP and the irregularity of the proximal cystic duct (arrowhead) is due to the tumor.
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hepatic arterial invasion [72].
More recently, hepatobiliary-specific contrast agents
have been developed to overcome the limitations of
non-specific extracellular fluid agents [73]. Since their
initial approval in Europe and Asia as early as 2005,
they have been widely available for the detection and
characterization of focal hepatic lesions [44]. Hepatobiliary-
specific contrast agents are divided into two main
categories: manganese-based (mangafodipir trisodium,
Teslascan®) and gadolinium-based (gadobenate dime-
glumine, MultiHance® and gadoxetic acid, Primovist®
in Europe and Eovist® in the United States) agents.
Teslascan is given as a slow infusion hence preventing
acquisition of dynamic images during the arterial and
portal venous phases [73]. This product has been re-
moved from the United States market from September
2004 but remains in use in Europe and Asia [74].
Gadolinium-based hepatobiliary-specific agents initially
distribute in the extracellular fluid compartment, sharing
the imaging properties of extracellular fluid agents during
the arterial and portal venous phases. However, they
are actively taken up by hepatocytes and excreted into
the bile. Hence, gadolinium-based hepatobiliary-specificagents provide the dual benefit of dynamic imaging cap-
ability as well as delayed hepatobiliary phase imaging [73].
In addition, fluid collections, ascites and fluid-containing
structures that can obscure findings on conventional T2W
MRCP are characteristically less conspicuous with T1W se-
quences used in contrast- enhanced MR cholangiography,
which may help in delineation of the biliary tree [73].
ERCP and percutaneous transhepatic cholangiography (PTC)
Both ERCP and PTC are invasive techniques that assess
biliary ducts and have the added advantage of obtaining
samples for histology. Due to their invasive nature espe-
cially with ERCP, which is more commonly performed,
there is risk of complications such as post-ERCP pancrea-
titis, cholangitis and bleeding. Vascular injury and death
can occur with both techniques. The sensitivity and speci-
ficity of cholangiography is about 75% with an accuracy of
95% for diagnosis of pCCA [75]. The possibility of obtain-
ing biopsy and brush cytology is promising but is not a
successful tool as desmoplastic reaction limits the number
of cells obtained by cytology. The routine brush cytology
has 9%-24% sensitivity and 61%-100% specificity for CCA
[76]. A repeat brushing may improve the sensitivity
to 44% [77]. Advanced cytologic techniques including
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hybridization (FISH) are used to increase the sensitivity of
cytology [78]. DIA increased the sensitivity to 39% in one
study [79] and FISH increased the sensitivity to 47% [80],
suggesting the moderate gain obtained with these tech-
niques. However, DIA and FISH improves sensitivity in
patients with PSC and elevated CA 19–9 (>20U/mL) to
56% and 86% respectively [81]. Per oral cholangioscopy
and intraductal ultrasound are emerging techniques and
larger experience with these new techniques is awaited.
Endoscopic ultrasound (EUS)
Recently, EUS has emerged as an important modality in
the diagnosis of CCA [82]. EUS-guided FNA (EUSFNA)
can be used for assessing the nature of biliary strictures
and for providing information on the extent of periduc-
tal disease and the presence of lymph node metastases
(Figure 11). It is gaining rapid popularity due to its
greater sensitivity for detecting malignancy in distal
tumors than does ERCP with brushings. EUSFNA has a
specificity of 100% and a sensitivity of 43-86% depending
upon location of the CCA [83]. In addition, EUSFNA
also avoids contamination of the biliary tree, which can
occur with ERCP [84]. Early data had shown that infor-
mation from EUSFNA had changed the management in
patients with previously non-diagnostic ERCP [82]. How-
ever, its use in imaging and staging proximal bile duct
lesions is uncertain with clinical experience still limited
[85]. At the same time, EUSFNA of primary lesions in po-
tential candidates for treatment with curative intent is still
discouraged due to the risk of peritoneal seeding [84].
PET
Experience with PET in extrahepatic CCA is limited. In
patients with areas of inflammation along the bile duct
associated with PSC, interpretation can be difficult as
areas of inflammation may have increased uptake and
desmoplastic areas of low cellularity may lead to possible
false negatives.
Staging and treatment
Accurate evaluation of tumour extent is necessary for
optimum management. The classic Bismuth-Corlette clas-
sification [86] for assessment of biliary tree involvement
has been incorporated into a new surgical staging system
that considers tumor size (>1 cm, 1-3 cm or > =3 cm),
tumor morphology, degree of specific location of hepatic
artery and portal vein encasement (vessel involvement >
180 degrees indicates encasement), volume of the poten-
tial liver remnant, presence of other liver diseases, status
of lymph nodes and distant metastases.
Surgery remains the mainstay of curative therapy, the
aim being complete tumor excision with negative histo-
logical margins, relief of obstruction and re-establishmentof bilio-enteric communication [33]. The following com-
plications preclude curative resection: involvement of the
right or left main hepatic duct to the level of the secondary
biliary radicals; atrophy of one hepatic lobe with contralat-
eral portal vein branch encasement or contralateral sec-
ondary biliary radical involvement; vascular encasement
or invasion (proper hepatic artery, bilateral hepatic arter-
ies, main portal vein); and metastases to lymph nodes,
peritoneal cavity or distant organs [33]. Radical resection
of pCCA has 5%-10% perioperative mortality rate [87].
Portal vein embolization is a valuable pre-operative
measure when extensive liver resections are performed.
The average 5-year survival rates following resection are
25%-40% [87] and the favourable outcome are associated
with R0 resection, no lymph node metastasis, absence of
perineural invasion, and well differentiated histological
grade [26].
Liver transplantation is not routinely performed for
pCCA but can increase survival in selected patients
wherein resection is not an option secondary to locally
advanced disease. Criteria for liver transplantation for
patients without PSC are: tumor less than 3 cm radial
diameter, no intrahepatic or extrahepatic metastases and
unresectability. In patients with PSC, the criteria are a
tumor less than 3 cm with no evidence of metastases
[6]. Radiation and chemotherapy have shown no benefit
[88]. Palliative surgery is often performed to relieve symp-
toms of obstruction [9] and jaundice relief with biliary
drainage.
Distal CCA (dCCA)
This subtype develops anywhere in the common bile
duct between the cystic duct origin and the ampulla of
Vater without its involvement (Figure 15). These are
separate from ampullary carcinomas. dCCA are thought
to arise from intraductal papillary neoplasm or biliary
intraepithelial neoplasia [28]. Histologically they are
predominantly well to moderately differentiated adenocar-
cinomas. When these arise in distal bile duct within the
pancreas, it’s difficult to distinguish it from cancer of the
head of the pancreas. Clinically, patients present with
symptoms of painless jaundice and cholangitis. Lymph
node metastases are less common than in the pCCA type.
Diagnosis and staging
Distinct features and imaging characteristics of this type
are not well known as these are frequently clubbed with
pCCA and referred to as extrahepatic CCA.
Ultrasound is useful to demonstrate the obstruction
level at the lower end of the bile duct and proximal dilata-
tion. CT and MRI with MRCP may demonstrate thicken-
ing and/or stricturing of bile duct (Figure 15) with
proximal duct dilatation and sometimes a mass (Figure 16).
The imaging can also help delineate invasion of vessels
Figure 15 Distal CCA. Common bile duct stricture due to grade 4 invasive carcinoma. Coronal T2-weighted image (a) and MRCP (b) image
showing a short segmental narrowing (arrow) with proximal dilatation. ERCP (c) showing a short segmental stricture representing the
invasive CCA.
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predictive for dCCA [89]. EUS is important in the pre-
operative evaluation of dCCA and EUS-FNA is very
specific for predicting unresectability [90]. Intraductal
ultrasonography may be useful in evaluation of invasion
of surrounding structures. Tumor depth invasion, lymph
node metastases, perineural, microscopic vascular inva-
sion and pancreatic invasion are significant predictors of
survival [91-94].
Treatment
Surgery is usually a pancreaticoduodenectomy (Whipple’s
procedure). The overall 5 –year survival rate of patients
with dCCA after complete resection is 27% with a median
survival of 25 months [21]. Nearly 2/3rd of patients with
dCCA who undergo surgery have involvement of lymph
nodes [21]. Negative tumor margins are the most im-
portant predictor of patient survival. Palliative treatment
comprises of relief of biliary obstruction with or without
chemotherapy.Figure 16 Distal CCA presenting as a polypoid mass with obstructive
(b) showing a soft tissue density filling defect in distal common bile duct (Gallbladder carcinoma (GbCA)
Gallbladder carcinoma (GbCA) is an uncommon but highly
lethal malignancy. GbCA is defined as cancer arising from
the gallbladder and the cystic duct [1]. Anatomic factors
promote early local invasion, with the ease by which this
tumor invades the liver and the biliary tree contributing to
its high mortality [95]. It also exhibits a propensity for in-
vasion to lymph nodes, hematogenous spread and capacity
to implant on peritoneal surfaces [96]. It is also often diag-
nosed late due to its non-specific nature of symptoms and
signs common to other benign diseases such as cholelith-
iasis or chronic cholecystitis [96]. The prognosis is poor
with a reported 5-year survival rate of less than 5% in
most large series [95]. Majority of cases of GbCA are dis-
covered incidentally at surgical exploration for benign
gallbladder disease [97].
Fewer than 5000 are diagnosed each year in the United
States with the incidence rate of 1 to 2 per 100,000 [98].
However, there is again a prominent geographic variability
in the incidence that correlates well with the prevalence ofjaundice. Contrast enhanced CT axial (a) and coronal reconstruction
arrow) representing the invasive grade 3 adenocarcinoma.
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South American and North Asian countries, and these
populations all share a high prevalence of gallstones and/
or Salmonella typhi infection, both recognized risk factors
[99]. The risk also seems higher in those with larger gall-
stones; Misra et al. [100] found that patients with stones
larger than three cm had a ten-fold higher risk of GbCA
compared to those with stones less than 1 cm.
Other risks factors include increasing age, female gender
(with women affected two to six times more often than in
men) [101], chronic cholecystitis, porcelain gallbladder,
gallbladder polyps, primary sclerosing cholangitis and a
congenital anomalous pancreaticobiliary duct junction
[102]. Lifestyle factors such as obesity, diabetes and
smoking are also contributory [20,95]. Exposure to che-
micals used in the rubber, automobile, wood finishing,
and metal fabricating industries have been associated
with an increased risk of GbCA as well [95].
GbCA occurs from dysplasia and metaplasia of the
epithelial lining of the gallbladder. Gastric metaplasia is
the most common metaplasia in gallbladders [3] and
intestinal metaplasia occurs with increasing age and in
association with gallstone disease [4]. Squamous meta-
plasia tends to be associated with gallstones and can lead
to squamous dysplasia or squamous cell carcinoma [4].
Adenomas occur in 0.3% -0.5% of the population and can
be pedunculated, sessile, single or multiple and are often
smaller than 2 cm [4]. The risk of malignant transform-
ation increases with the size of the adenoma and the
amount of papillary pattern. Approximately 98% of GbCA
are of epithelial origin, with more than 90% identified as
adenocarcinomas. Adenocarcinomas may be well, moder-
ately, or poorly differentiated depending on the degree of
gland formation [95]. The remaining subtypes include
adenosquamous or squamous cell carcinoma, small cell
neuroendocrine tumors, sarcoma, and lymphomas [97].
Most of these tumors originate in the gallbladder fundus
(60%) with the remainder in the body (30%) and neck
(10%) [91]. Rare non-epithelial tumors include sarcomas,
lymphomas, carcinoid tumors, and metastases.
Diagnosis
Clinical diagnosis of GbCA is challenging due to lack of
specific signs and symptoms and therefore diagnosis is
made quite late into the disease or as an incidental find-
ing after cholecystectomy done for cholecystitis or other
reasons. Most of the patients present with right upper
quadrant abdominal pain. Weight loss, anorexia, nausea
and vomiting are commonly associated [1]. Raised serum
carcinoma embryonic antigen (CEA) levels may be useful
to improve diagnosis.
Imaging studies may reveal a mass replacing the normal
gallbladder, diffuse or focal thickening of the gallbladder
wall (Figures 17 and 18), polypoid mass (Figure 19) withinthe gallbladder lumen or as a gallbladder fossa mass [103].
Mass replacing the gallbladder fossa is the most common
presentation (Figure 17). Adjacent organ invasion, primar-
ily involving the liver and biliary obstruction is often
present at diagnosis. Periportal and peripancreatic lymph
nodes, hematogenous and peritoneal metastases may also
be seen [95]. About 25% of GbCA present as an intralum-
inal mass and they tend to have better prognosis as they
are usually confined by the muscularis propria. GbCA pre-
senting as focal or diffuse mural thickening is the least
common and most difficult to diagnose. Benign conditions
that are associated with diffuse wall thickening including
acute and chronic cholecystitis, adenomyomatosis, hepa-
titis and inadequate bladder distension are more common.
Ultrasound and EUS
Ultrasonography is most often the first imaging modality
in investigating gallbladder disease due to its relatively
low cost and ease of availability [96]. However, in the
case of GbCA, although ultrasonography can detect late-
stage tumor with high sensitivity (Figure 9), its use is
limited in early lesion diagnosis and staging [103]. This
limitation can be overcome by combining endoscopy
with ultrasound (EUS) and in recent years, endoscopic
ultrasound has gained increasing popularity in assessment
of GbCA. This technique enables assessment of the depth
of tumor invasion into the wall of the gallbladder and
presence of lymphadenopathy at the porta hepatis and
peripancreatic regions. It can also provide a means of
obtaining bile for cytological analysis that has been found
to have 73% sensitivity for the diagnosis of GbCA [104].
Discontinuous thickening of the gallbladder mucosa,
diffuse thickening of the gallbladder wall (>12 mm),
mural calcification, a mass protruding into the lumen, a
fixed mass in the gallbladder, and loss of the interface
between the liver and the gallbladder are all signs com-
monly associated with gallbladder cancer [105]. Nodular
and papillary GbCA is more likely to be associated with
a mass and easily detected as compared to infiltrative
carcinoma. Conventional US appears to be quite reliable
in the detection of masses and the extent of hepatic
invasion, but it is limited in its ability to detect lymph
node and peritoneal disease. Polypoid carcinomas have
homogeneous tissue texture and are fixed to the gallbladder
at their base. Small polypoid carcinomas are difficult to
differentiate from a cholesterol polyp, adenoma, adherent
stone, sludge or a blood clot.
CT
CT is a better modality for evaluation of thickness of the
portions of the gallbladder wall that are obscured on
ultrasound. Wall thickening remains diagnostically chal-
lenging as it mimics the appearance of more common
inflammatory conditions of the gallbladder. Marked wall
Figure 17 Gall bladder carcinoma. Contrast enhanced axial CT image (a) and coronal reformat (b) showing hypodense thickening of the gall
bladder wall representing the carcinoma (arrow) with involvement of the adjacent liver. The thickening covers more than half of gall bladder
lumen (*).
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or significant asymmetry (Figure 17) should raise concerns
for malignancy [95]. Diffuse symmetric wall thickening is
more likely to suggest a non-neoplastic process [106].
GbCA are usually hypodense on unenhanced CT with
up to 40% showing hypervascular foci of enhancement
equal or greater than that of the adjacent hepatic paren-
chyma [106]. Contrast enhancement may be retained in
fibrous stromal components of gallbladder carcinoma
during the portal venous and delayed phases – this can
potentially aid in differentiating gallbladder carcinomas
from hepatocellular carcinomas (which have a greater
tendency to washout in these phases) (Figure 17).
Prevalence of lymphatic spread is high, progressing
from the gallbladder fossa through the hepatoduodenal
ligament to nodal stations near the pancreatic head.
Masses around the common bile duct and pancreatic
head may mimic a pancreatic head carcinoma [95].
The sensitivity of contrast enhanced CT (ceCT) in
detecting gallbladder neoplasms has been reported toFigure 18 Gall bladder carcinoma. The gallbladder and gall bladder foss
ultrasound (a, b) and heterogeneous hypodense mass (*) on contrast enha
of gallbladder carcinoma during the portal venous (c) and delayed phasesbe as high as 90% and is particularly effective in detecting
T2 or greater tumors [107]. Appearances on ceCT can
include a low-attenuation mass, enhancing mass with
ill-defined borders, eccentric gallbladder wall thickening
or a fungating mass. The information obtained through
ceCT is also critical in assessing resectability of gallbladder
tumors; it provides valuable information on local and vas-
cular invasion as well as hematogenous and lymph node
metastases, although its reliability in staging lymph node
disease is not always accurate.
MRI
On MRI, GbCA are usually hypo to iso-intense on T1W
and moderately hyperintense on T2W sequences (Figure 19)
with enhancement characteristics similar to that of CT
[103]. MRI may be more useful relative to CT in the as-
sessment of focal or diffuse mural thickening as it may be
able to distinguish GbCA from benign entities such as
adenomyomatosis and xanthogranulomatous cholecystitis.
Rokitansky-Aschoff sinuses in adenomyomatosis are besta is replaced by a large heterogeneous mass of mixed echogenicity on
nced CT with enhancement of the fibrous stromal component (arrow)
(d).
Figure 19 Gall bladder carcinoma arising from the fundus of the gall bladder (arrow) seen as an iso to hyperintense mass on
T2-weighted (a) and hypointense mass on T1-weighted (b) images and shows enhancement on post gadolinium enhanced image (c).
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phages found in xanthogranulomatous cholecystitis can
be demonstrated as a drop-out in signal in opposed phase
images.
MR angiography and MRCP can be added to facilitate
the diagnosis of vascular and biliary infiltration that is
essential before attempting curative resection. Any focal
or eccentric stenosis, irregularity of the lumen or abrupt
amputation is suggestive of invasion.
PET
An intense accumulation of 18 F-FDG in the region of
the gallbladder suggests malignancy although it lacks
specificity in differentiating primary gallbladder carcin-
oma from other malignant lesions such as HCC, CCA and
metastatic disease [49]. In addition, benign inflammatory
lesions can also accumulate FDG and result in false posi-
tive interpretations. PET however has a promising role in
the detection of unsuspected metastases that may modify
staging and therapy [96].
Staging and treatment
GbCA are staged according to UICC/AJCC staging sys-
tem [50]. Invasion of portal vein, hepatic artery or two
or more extrahepatic organs is considered T4 disease.
Surgery again, is the only potential curative therapy [108].
As mentioned above, GbCA is most often discovered
incidentally at surgical exploration for benign gallbladder
disease. The surgeon then has to exercise clinical judgment
during the operation; completing the cholecystectomy
alone, obtain an intra-operative frozen section of the gall-
bladder (which if positive would lead to a more extensive
resection) or proceed with resection of the gallbladder
along with a rim of liver tissue. Although an intraoperative
frozen section can reliably indicate the presence of ma-
lignancy, it cannot reliably predict the depth of tumor
invasion. External beam radiation therapy and systemic
chemotherapy have improved survival in patients with
negative resection margins [109].
If the cancer is locally unresectable, chemotherapy or
chemoradiotherapy can be considered. There is no indi-
cation for radical surgery for the purpose of debulkingand attempted resection should only be accepted if it is
possible to achieve complete resection [110]. The goal of
palliation in advanced gallbladder cancer is relief of pain
and jaundice along with prolongation of life. Placement
of endoscopic or percutaneous biliary prostheses may be
performed [96].
Ampullary carcinoma
The ampulla of Vater comprises the junction of the biliary
and pancreatic ducts and is surrounded by the sphincter
of Oddi; it traverses a dehiscence of the duodenal wall and
terminates as the major duodenal papilla [111]. Ampullary
carcinomas are defined as those that arise within this
ampullary complex, distal to the bifurcation of the distal
common bile and pancreatic ducts. The duodenal papilla
is lined by intestinal mucosa, whereas the ampullary por-
tions are covered by simple mucinous epithelium, as in
the normal bile duct – malignancies of the ampulla can
arise from these two cell types. Pancreaticobiliary type of
differentiation is more common than intestinal [112].
Intestinal type is associated with better survival [7]. The
ampulla is surrounded by the parenchyma of the pancre-
atic head and the duodenum and this area is called the
periampullary region within 2 cm of the ampulla.
Ampullary carcinoma is rare, with an incidence rate of
4–6 per million [113]. However, it tends to show a better
prognosis as compared to the aforementioned biliary
malignancies because it can be detected at a relatively
early stage owing to biliary obstruction resulting in jaun-
dice. The intestinal type ampullary carcinoma is relatively
more common, and its incidence can increase 200 to 300
fold among genetically susceptible groups such as patients
with hereditary polyposis syndromes [114]. The average age
at diagnosis of sporadic ampullary carcinomas is 60–70
years old with patients with an inherited polyposis
syndrome presenting at an earlier age, due in part to
surveillance programs [115].
Biliary dilatation is seen in 75% of cases and pancreatic
ductal dilatation in 67% [116]. Histology of primary
ampullary neoplasms tends to resemble adenomas and
adenocarcinomas of intestinal origin rather than a
pancreaticobiliary origin [117]. True ampullary cancers
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nancies of pancreatic or extrahepatic biliary origin with
higher resectability rates and a 30-50% survival rate [118].
Diagnosis and imaging
Differentiating a primary ampullary carcinoma from the
more prevalent periampullary malignancies can be chal-
lenging. It may not be possible to determine the tissue
origin until resection and histopathological evaluation.
CT
Although CT (Figure 20) can detect masses obstructing
the distal common bile duct, it usually is not sensitive
enough to allow visualization of small ampullary tumors
within the duodenal lumen. CT also lacks the spatial
resolution to determine exact extent of local invasion
but is generally useful for assessing presence of lymph-
adenopathy and distant metastatic disease. Marked and
abrupt dilatation of the distal bile duct or pancreatic
duct in the absence of stones or pancreatitis is highly
suggestive of ampullary carcinoma [111].
ERCP
In a patient with jaundice secondary to malignant bile
duct obstruction, an ERCP is preferred as it permits
biopsy and placement of a stent for biliary decompression
if necessary. Although it allows visualization of the neo-
plasm, it cannot determine extent of local invasion. If an
exophytic ampullary tumor is discovered, malignancy is
highly suggestive if the mass is ulcerated or greater than
3 cm in size [119].
MRI and MRCP
Most appear as a discrete nodular mass at the distal
margin of the pancreaticobiliary junction and are
hypointense on T2W imaging [111]. The remainder
can appear as irregular periductal thickening aroundFigure 20 Ampullary carcinoma. Contrast enhanced axial CT (a) and cor
carcinoma in the ampulla of the bile duct.the pancreaticobiliary junction or papillary bulging into
the duodenum [111]. MRCP is a non-invasive method of
imaging the pancreaticobiliary tree and is used in those
who either cannot tolerate the more invasive ERCP or in
whom a large tumor occludes the orifice of the duct hence
preventing cannulation and duct opacification. The neo-
plasm appears as a filling defect within the duodenal
lumen with characteristic delayed enhancement.
EUS
EUS is found to be as sensitive as ERCP and superior to
CT for the detection of small ampullary tumors [120].
EUS accurately displays the depth of tumor invasion into
the duodenum and local extension to adjacent structures.
EUS has been found to be the most accurate modality to
assess local staging of ampullary tumors with several stud-
ies achieving accuracies of 70–90% [121-123]. However, as
biliary and pancreatic sphincterotomy and stent place-
ment cannot be attained during EUS, those who require
these therapeutic interventions must also undergo an
ERCP.
Staging and treatment
The TNM staging defines T1 stage tumor as limited to
ampulla of Vater [50]. Tumors infiltrating duodenal wall
are T2 and those infiltrating pancreas are T3. T2 tumors
infiltrate into peripancreatic tissue or surrounding organs.
Lymph node metastases around the superior mesenteric
artery, the celiac trunk or pancreatic tail are considered as
metastases. As in the former two biliary malignancies, the
only potentially curative treatment for ampullary carcinoma
is surgical resection. Entire tumor resection with negative
margins is essential for cure. A Whipple’s operation is
regarded as the standard approach for ampullary carcin-
oma; surgical outcomes have improved with time with
rates of potentially curative resection increased from
approximately 80 to over 90% [118,124].onal reformat (b) showing a small polypoid mass (arrow) representing
Hennedige et al. Cancer Imaging 2014, 14:14 Page 18 of 21
http://www.cancerimagingjournal.com/content/14/1/14An ampullectomy may be considered in those with
early low-grade tumors. Some have proposed that local
resection is a reasonable approach for small (<6 mm)
well-differentiated tumors that do not penetrate through
the ampullary musculature [125]. Despite the high rate of
potentially curative resections, more than 50% of patients
succumb to recurrent disease, suggesting the need for ad-
juvant therapy. Although there is no consensus regarding
the optimal management of patients after resection, the
benefit from post-operative chemoradiotherapy has been
suggested by several studies [126].
Other malignant neoplasms of the bile ducts include
lymphomas, leiomyosarcomas, carcinoid tumours and
metastases in adults. Embryonal rhabdomyosarcoma can
occur in children and is the second most common cause
of jaundice in pediatric population. Readers are referred
to literature elsewhere for more details on these rare
neoplasms.
Conclusion
Malignancies of the biliary tract are uncommon but
associated with poor prognosis due to their late detection.
CT, MRI with MRCP and EUS are most important in
detection of early stage tumors and for pre-operative
planning. MRI and MRCP is the single most useful moda-
lity for diagnosis of biliary malignancies. Surgical resection
is the only curative treatment available although the 5-year
survival is still poor compared to other tumors. Overall,
imaging plays a critical role in the management of these
malignancies and requires a combined evaluation with
one or more modalities along with clinical features and
histological grade of the malignancy.
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